ALUMIS INC. (ALMS) Q3 2025 10-Q Quarterly Report

Filed: Nov 13, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR

ALUMIS INC. (ALMS) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 13, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

ALUMIS INC. Q3 2025 10-Q Analysis

Risk Factors

  • New litigation risk from securities class action lawsuit post-ACELYRIN Merger alleging disclosure violations in Phase 2b trial, motion to dismiss pending as of May 3, 2024
  • Updated market risk: post-merger stock ownership split 52% vs 48% increases potential stock price volatility due to large share sales
  • Regulatory risk: emerging growth company status allows reduced SEC reporting and delayed auditor attestation under Sarbanes-Oxley, possibly deterring investors
  • Operational risk: anti-takeover provisions, including classified board and preferred stock issuance without stockholder approval, can delay change of control transactions
  • Financial risk: concentration of 40% voting stock among insiders limits public float, restricting liquidity and potentially depressing trading price

Get deeper insights on ALUMIS INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.